| dc.contributor.author | Giovannoni, G | en_US |
| dc.contributor.author | Baker, D | en_US |
| dc.contributor.author | Schmierer, K | en_US |
| dc.date.accessioned | 2017-11-17T14:47:41Z | |
| dc.date.issued | 2015-01-01 | en_US |
| dc.date.submitted | 2017-02-02T00:20:53.300Z | |
| dc.identifier.issn | 2211-0348 | en_US |
| dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/28786 | |
| dc.description.abstract | ©2014 Elsevier B.V. All rights reserved. If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking of proof-of-concept studies using off-patent medications? Without a financial incentive it is very difficult to repurpose off patent drugs for a new indication. Therefore, we need a political solution to allow the repurposing of off-patent drugs by other stakeholders or Big Pharma. | en_US |
| dc.format.extent | 3 - 5 | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Multiple Sclerosis and Related Disorders | en_US |
| dc.title | The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? | en_US |
| dc.type | Article | |
| dc.rights.holder | © 2014 Elsevier B.V. All rights reserved. | |
| dc.identifier.doi | 10.1016/j.msard.2014.11.005 | en_US |
| pubs.issue | 1 | en_US |
| pubs.notes | No embargo | en_US |
| pubs.publication-status | Published | en_US |
| pubs.volume | 4 | en_US |
